Please provide your email address to receive an email when new articles are posted on . In a small study, cardiopulmonary exercise testing identified significant abnormalities, including dysfunctional ...

In a recent study posted to the medRxiv* pre-print server, researchers demonstrated reduced exercise capacity due to persistent cardiopulmonary symptoms among coronavirus disease 2019 (COVID-19) ...

Cardiopulmonary exercise testing (CPET), also known as ergospirometry, can be used for early detection of respiratory disorders in overweight and obese individuals. This is the main finding of a study ...

The assessment of patients with suspected or confirmed pulmonary arterial hypertension (PAH) and secondary pulmonary hypertension (PH) continues to evolve and, in recent years, evidence demonstrating ...

"ATTR amyloidosis was characterized by distinct patterns of functional impairment across all disease phenotypes, attributable to multiple physiological mechanisms. Multiple CPET parameters were ...

Cardiopulmonary exercise testing may be useful in characterizing distinct patterns of functional impairment in patients with transthyretin amyloidosis (ATTR), a multisystem, life-threatening disease ...

Patients who have unexplained dyspnea months after recovering from COVID-19 often have objective signs of breathing problems on cardiopulmonary exercise testing (CPET) and meet criteria for myalgic ...

Many patients with symptoms of long COVID have reduced exercise capacity, which if better understood might be helpful in managing their treatment, according to a systematic review and meta-analysis of ...

Correspondence to Dr Meagan M Wasfy, Cardiovascular Performance Program, Massachusetts General Hospital, Boston, MA 02114, USA; mwasfy{at}partners.org Objectives Persistent or late-onset ...

A meta-analysis suggested with low confidence that symptomatic long COVID was associated with decreased exercise capacity on cardiopulmonary exercise testing up to 3 months after initial SARS-COV-2 ...

Pharmacodynamic separation (PDS) of gemcitabine (Gem) and the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (Pts) with advanced pancreatic cancer: Phase II results. This ...